Have you stopped receiving our weekly e-newsletter?

Europe

Author: Joe McAweaneyPublished: 12 July 2018

Prep: Cook: Serves:

Due to recent changes in EU law, you must ‘opt-in’ to continue to receive our e-newsletter

On 25 May 2018 General Data Protection Regulation (GDPR) laws were passed by the European Union, significantly changing the ways in which businesses and public sector organisations must handle data.

The new laws mean that all consumer information held before this date must be deleted, meaning that people must ‘opt-in’ to keep receiving communications from organisations. For Parkinson’s Life, this means that if you want to keep receiving our weekly e-mail newsletter you must let us know – regardless of whether you have signed up in the past or not. Legally, we must delete your data and cannot communicate with you if you have not signed up.

To sign up, please click ‘subscribe’ in the top right hand corner of our website and fill out the form.

We are very proud of the work we do here at Parkinson’s Life, and are looking forward to communicating with as many of you as possible in the future.

Last Month

Next Month

Go Back

Share this story

Comments

Global update

Think twice: the deadly risk of fake drugs

Learn how to how to tell a fake pill from a real one

Aspiring Parkinson’s nurses urged to apply for “hands-on” summer school in Portugal

A unique opportunity to bring Parkinson’s nurses together

Dancing across the globe for Parkinson’s

How a New York dance class spread around the world

World War II weapon antidote could treat Parkinson’s

Researchers at Purdue University, US, are studying a World War II chemical weapon antidote that they believe could be used to treat Parkinson’s. It is believed the antidote, called dimercaprol, may be able to remove acrolein – a toxin that poisons neurons and can lead to the development of Parkinson’s disease. In addition to this, researchers believe dimercaprol can increase the survival rate of brain cells, improve mobility and reduce symptoms of pain. Riyi Shi, professor of neuroscience and biomedical engineering at Purdue University, said: “Our studies show that by removing the toxin (acrolein) from the brain, we are not just reducing the symptoms of Parkinson’s disease but also significantly reversing the damage of Parkinson’s disease. This could actually provide a new treatment for Parkinson’s patients.”

Repurposed cancer drug shows promise for Parkinson’s

Researchers at the Oxford Parkinson’s Disease Centre, UK, have repurposed an experimental cancer drug – called tasquinimod – as a potential treatment for Parkinson’s. The study – funded by Parkinson’s UK and published in science journal ‘Cell Stem Cell’ – has been tested on a total of 10 patients so far. As part of the research, the study grew brain cells from donated skin cell samples of people living with a rare genetic form of Parkinson’s – this process was then repeated on people with a common non-genetic form of the condition. Researchers found that tasquinimod can block HDAC4, a protein that causes Parkinson’s genes to become inactive. Professor Richard Wade-Martins, co-lead author of the study, said: “We think that switching off these genes in brain cells may play a vital role in the cell damage and death that occurs in Parkinson’s.”

Research survey assesses impact of holidays on Parkinson’s symptoms

The Radboud University Medical Center, Netherlands, is seeking participants for an online survey assessing the effects of a holiday on Parkinson’s. The study will assess whether a vacation can have physical and mental benefits for people living with the condition. It will also look at which specific factors, such as temperature and physical activity, can alleviate or increase symptoms. The Michael J Fox Foundation has approved the study’s protocol. Participants can sign up to complete the 20-minute survey online. The survey is open to anyone over 18 who has Parkinson’s and has been on vacation once or more between 1 June 2016 and 30 September 2018. Marjan Faber, the study’s daily supervisor, said: “If the study is able to identify decisive factors, those can act as a starting point for novel approaches in care for people with Parkinson’s disease.” To apply please visit research platform ParkinsonNEXT.

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
Captcha
*
- By proceeding you agree to our
Phone
This field is for validation purposes and should be left unchanged.

Have you stopped receiving our weekly e-newsletter?

Europe

Author: Joe McAweaneyPublished: 12 July 2018

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Global update

Think twice: the deadly risk of fake drugs

PD in Practice

Aspiring Parkinson’s nurses urged to apply for “hands-on” summer school in Portugal

Perspectives

Dancing across the globe for Parkinson’s

World War II weapon antidote could treat Parkinson’s

Repurposed cancer drug shows promise for Parkinson’s

Research survey assesses impact of holidays on Parkinson’s symptoms

{title}

Subscribe

Have you stopped receiving our weekly e-newsletter?

Europe

Author: Joe McAweaneyPublished: 12 July 2018

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Related articles

Global update

Think twice: the deadly risk of fake drugs

PD in Practice

Aspiring Parkinson’s nurses urged to apply for “hands-on” summer school in Portugal

Perspectives

Dancing across the globe for Parkinson’s

World War II weapon antidote could treat Parkinson’s

Repurposed cancer drug shows promise for Parkinson’s

Research survey assesses impact of holidays on Parkinson’s symptoms

{title}

Subscribe

Sign in